References
Harada G, Gongora ABL, Costa CM et al (2020) TRK inhibitors in non-small cell lung cancer. Curr Treat Options Oncol. https://doi.org/10.1007/s11864-020-00741-z
Märkl B, Hirschbühl K, Dhillona C (2019) NTRK-fusions—a new kid on the block. Pathol Res Pract. https://doi.org/10.1016/j.prp.2019.152572
Cocco E, Scaltriti M, Drilon A (2018) NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol. https://doi.org/10.1038/s41571-018-0113-0
Okamura R, Boichard A, Kato S et al (2018) Analysis of NTRK alterations in pan-cancer adult and pediatric malignancies: implications for NTRK-targeted therapeutics. JCO Precis Oncol. https://doi.org/10.1200/PO.18.00183
Acknowledgements
We appreciate for the kindly assistance from Mr. Chuang Qi, Mrs. Si Li, Mr. Wanglong Deng, and Mr. Guanghua Lu in Jiangsu Simcere Diagnostics.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors have declared no conflicts of interest.
Ethical approval
This article does not contain any studies with human participants or animals performed by any of the authors.
Informed consent
Informed consent was obtained from an individual participant included in the case.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Yang, S., Li, L., Chen, D. et al. EPS15–NTRK1: a novel NTRK1 oncogenic fusion in patient with lung adenocarcinoma. J Cancer Res Clin Oncol 146, 3389–3392 (2020). https://doi.org/10.1007/s00432-020-03416-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-020-03416-2